ArticleDigestive diseases and sciences2026
Propofol Sedation with a Target-Controlled Infusion Pump and Bispectral Index Monitoring System in Older Patients Undergoing Antegrade Balloon-Assisted Enteroscopy.
Article in Digestive diseases and sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAdequate sedation is essential for balloon-assisted enteroscopy (BAE). While propofol sedation using target-controlled infusion (TCI) and bispectral index (BIS) monitoring is considered effective, its safety in older patients undergoing antegrade BAE remains unclear. This study evaluated the safety and efficacy of TCI/BIS-guided propofol sedation in older patients.
methodsIn this retrospective study, 369 patients who underwent antegrade BAE under propofol sedation between April 2017 and March 2024 were categorized into three age groups: younger (< 50 years, N = 123), middle-aged (50-69 years, N = 121), and older (≥ 70 years, N = 125). Propofol dosage, sedation-related adverse events, and procedural outcomes were compared. Multivariate analysis was compared to identify risk factors for major sedation-related events, including hypoxemia, hypotension, bradycardia.
resultsOlder patients required significantly lower target concentrations and total doses of propofol than younger and middle-aged patients (younger: 2.0 µg/mL, middle-aged: 1.6 µg/mL, older: 1.4 µg/mL, P < 0.01; younger: 414 mg, middle-aged: 312 mg, older: 212 mg, P < 0.01). Induction time was significantly longer in younger patients (P < 0.01). Major sedation-related adverse event rates did not significantly differ by age group. Multivariate analysis showed no association between age and adverse events. Low preoperative systolic blood pressure increased the risk of hypotension (OR = 2.32), chronic respiratory disease increased the risk of hypoxemia (OR = 2.97), and ASA class III increased the risk of bradycardia (OR = 3.38). All procedures were completed successfully without severe adverse events.
conclusionTCI/BIS-guided propofol sedation may be acceptable for older patients undergoing antegrade BAE, who require a lower propofol dose than younger patients.
Indexed as
Identifiers
41046481What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.